IBRX•benzinga•
ImmunityBio Announces Long-term Results From QUILT-3.032 Study Of ANKTIVA Plus BCG For Treatment Of Adult Patients With BCG-unresponsive NMIBC CIS, With Or Without Papillary Disease
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 28, 2025 by benzinga